{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T03:36:55Z","timestamp":1773200215742,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T00:00:00Z","timestamp":1668384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T00:00:00Z","timestamp":1668384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Although asthma does not appear to be a risk factor for severe coronavirus disease 2019 (COVID-19), outcomes could vary for patients with different asthma subtypes. The objective of this analysis was to compare COVID-19 outcomes in real-world cohorts in the United States among patients with asthma, with or without evidence of allergy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In a retrospective analysis of the COVID-19 Optum electronic health record dataset (February 20, 2020\u2013January 28, 2021), patients diagnosed with COVID-19 with a history of moderate-to-severe asthma were divided into 2 cohorts: those with evidence of allergic asthma and those without (nonallergic asthma). After 1:1 propensity score matching, in which covariates were balanced and potential bias was removed, COVID-19 outcomes were compared between cohorts.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>From a COVID-19 population of 591,198 patients, 1595 patients with allergic asthma and 8204 patients with nonallergic asthma were identified. After propensity score matching (<jats:italic>n<\/jats:italic>\u2009=\u20091578 per cohort), risk of death from any cause after COVID-19 diagnosis was significantly lower for patients with allergic vs nonallergic asthma (hazard ratio, 0.48; 95% CI 0.28\u20130.83; <jats:italic>P<\/jats:italic>\u2009=\u20090.0087), and a smaller proportion of patients with allergic vs nonallergic asthma was hospitalized within\u2009\u2212\u20097 to\u2009+\u200930\u00a0days of COVID-19 diagnosis (13.8% [<jats:italic>n<\/jats:italic>\u2009=\u2009217] vs 18.3% [<jats:italic>n<\/jats:italic>\u2009=\u2009289]; <jats:italic>P<\/jats:italic>\u2009=\u20090.0005). Among hospitalized patients, there were no significant differences between patients with allergic or nonallergic asthma in need for intensive care unit admission, respiratory support, or COVID-19 treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Asthma subtype may influence outcomes after COVID-19; patients with allergic asthma are at lower risk for hospitalization\/death than those with nonallergic asthma.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12890-022-02230-5","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T08:08:49Z","timestamp":1668413329000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Patients with allergic asthma have lower risk of severe COVID-19 outcomes than patients with nonallergic asthma"],"prefix":"10.1186","volume":"22","author":[{"given":"Thomas R.","family":"Murphy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Busse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecile T. J.","family":"Holweg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yamina","family":"Rajput","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karina","family":"Raimundo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig S.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arpamas","family":"Seetasith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachin","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmar","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Kaner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,14]]},"reference":[{"issue":"7798","key":"2230_CR1","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, Si H-R, Zhu Y, Li B, Huang C-L, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270\u20133.","journal-title":"Nature"},{"key":"2230_CR2","doi-asserted-by":"crossref","unstructured":"Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497\u2013506.","DOI":"10.1016\/S0140-6736(20)30183-5"},{"issue":"7","key":"2230_CR3","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/S2213-2600(21)00013-8","volume":"9","author":"CI Bloom","year":"2021","unstructured":"Bloom CI, Drake TM, Docherty AB, Lipworth BJ, Johnston SL, Nguyen-Van-Tam JS, Carson G, Dunning J, Harrison EM, Baillie JK, et al. Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK. Lancet Respir Med. 2021;9(7):699\u2013711.","journal-title":"Lancet Respir Med"},{"key":"2230_CR4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ijid.2020.07.029","volume":"99","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Yang Q, Chi J, Dong B, Lv W, Shen L, Wang Y. Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: a systematic review and meta-analysis. Int J Infect Dis. 2020;99:47\u201356.","journal-title":"Int J Infect Dis"},{"issue":"12","key":"2230_CR5","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1164\/rccm.202007-2794OC","volume":"202","author":"TM Drake","year":"2020","unstructured":"Drake TM, Docherty AB, Harrison EM, Quint JK, Adamali H, Agnew S, Babu S, Barber CM, Barratt S, Bendstrup E, et al. Outcome of hospitalization for COVID-19 in patients with interstitial lung disease.\u00a0an international multicenter study. Am J Respir Crit Care Med. 2020;202(12):1656\u201365.","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"2230_CR6","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/S2213-2600(21)00095-3","volume":"9","author":"P Aveyard","year":"2021","unstructured":"Aveyard P, Gao M, Lindson N, Hartmann-Boyce J, Watkinson P, Young D, Coupland CAC, Tan PS, Clift AK, Harrison D, et al. Association between pre-existing respiratory disease and its treatment, and severe COVID-19: a population cohort study. Lancet Respir Med. 2021;9(8):909\u201323.","journal-title":"Lancet Respir Med"},{"key":"2230_CR7","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1136\/bmjebm-2020-111506","volume":"26","author":"J Hartmann-Boyce","year":"2020","unstructured":"Hartmann-Boyce J, Gunnell J, Drake J, Otunla A, Suklan J, Schofield E, Kinton J, Inada-Kim M, Hobbs FDR, Dennison P. Asthma and COVID-19: review of evidence on risks and management considerations. BMJ Evid Based Med. 2020;26:195.","journal-title":"BMJ Evid Based Med"},{"issue":"2","key":"2230_CR8","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.jaci.2020.06.001","volume":"146","author":"Z Zhu","year":"2020","unstructured":"Zhu Z, Hasegawa K, Ma B, Fujiogi M, Camargo CA Jr, Liang L. Association of asthma and its genetic predisposition with the risk of severe COVID-19. J Allergy Clin Immunol. 2020;146(2):327\u20139.e4.","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"2230_CR9","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/S2213-2600(20)30415-X","volume":"8","author":"A Schultze","year":"2020","unstructured":"Schultze A, Walker AJ, MacKenna B, Morton CE, Bhaskaran K, Brown JP, Rentsch CT, Williamson E, Drysdale H, Croker R, et al. Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform. Lancet Respir Med. 2020;8(11):1106\u201320.","journal-title":"Lancet Respir Med"},{"issue":"4","key":"2230_CR10","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2500\/aap.2021.42.210041","volume":"42","author":"AN Sitek","year":"2021","unstructured":"Sitek AN, Ade JM, Chiarella SE, Divekar RD, Pitlick MM, Iyer VN, Wang Z, Joshi AY. Outcomes among patients with COVID-19 and asthma: a systematic review and meta-analysis. Allergy Asthma Proc. 2021;42(4):267\u201373.","journal-title":"Allergy Asthma Proc"},{"issue":"4","key":"2230_CR11","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1093\/intimm\/dxab107","volume":"34","author":"YD Gao","year":"2022","unstructured":"Gao YD, Agache I, Akdis M, Nadeau K, Klimek L, Jutel M, Akdis CA. The effect of allergy and asthma as a comorbidity on the susceptibility and outcomes of COVID-19. Int Immunol. 2022;34(4):177\u201388.","journal-title":"Int Immunol"},{"key":"2230_CR12","doi-asserted-by":"crossref","unstructured":"Caminati M, Vultaggio A, Matucci A, Senna G, Almerigogna F, Bagnasco D, et al. Asthma in a large COVID-19 cohort: prevalence, features, and determinants of COVID-19 disease severity. Respir Med. 2021;176:106261.","DOI":"10.1016\/j.rmed.2020.106261"},{"key":"2230_CR13","doi-asserted-by":"crossref","unstructured":"Eger K, Hashimoto S, Braunstahl GJ, Brinke AT, Patberg KW, Beukert A, et al. Poor outcome of SARS-CoV-2 infection in patients with severe asthma on biologic therapy. Respir Med.\u00a02020;177:106287.","DOI":"10.1016\/j.rmed.2020.106287"},{"issue":"4","key":"2230_CR14","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.jaci.2020.08.008","volume":"146","author":"JM Yang","year":"2020","unstructured":"Yang JM, Koh HY, Moon SY, Yoo IK, Ha EK, You S, Kim SY, Yon DK, Lee SW. Allergic disorders and susceptibility to and severity of COVID-19: a nationwide cohort study. J Allergy Clin Immunol. 2020;146(4):790\u20138.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"2230_CR15","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/all.14972","volume":"77","author":"LE Eggert","year":"2022","unstructured":"Eggert LE, He Z, Collins W, Lee AS, Dhondalay G, Jiang SY, Fitzpatrick J, Snow TT, Pinsky BA, Artandi M, et al. Asthma phenotypes, associated comorbidities, and long-term symptoms in COVID-19. Allergy. 2022;77(1):173\u201385.","journal-title":"Allergy"},{"key":"2230_CR16","unstructured":"Emergency use ICD codes for COVID-19 disease outbreak [https:\/\/www.who.int\/standards\/classifications\/classification-of-diseases\/emergency-use-icd-codes-for-covid-19-disease-outbreak]."},{"key":"2230_CR17","unstructured":"Asthma codes for ICD-10 [https:\/\/www.aaaai.org\/Aaaai\/media\/MediaLibrary\/PDF%20Documents\/Practice%20Management\/finances-coding\/Asthma-Codes-ICD-10.pdf]."},{"issue":"1","key":"2230_CR18","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","volume":"70","author":"PR Rosenbaum","year":"1983","unstructured":"Rosenbaum PR, Rubin DM. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41\u201355.","journal-title":"Biometrika"},{"issue":"5","key":"2230_CR19","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383.","journal-title":"J Chronic Dis"},{"key":"2230_CR20","doi-asserted-by":"crossref","unstructured":"Lee SW. Methods for testing statistical differences between groups in medical research: statistical standard and guideline of Life Cycle Committee. Life Cycle. 2022;2:e1.","DOI":"10.54724\/lc.2022.e1"},{"key":"2230_CR21","doi-asserted-by":"crossref","unstructured":"SW L. Regression analysis for continuous independent variables in medical research: statistical standard and guideline of Life Cycle Committee. Life Cycle. 2022;2:e3.","DOI":"10.54724\/lc.2022.e3"},{"issue":"5","key":"2230_CR22","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/j.jaci.2007.07.056","volume":"120","author":"SJ Arbes Jr","year":"2007","unstructured":"Arbes SJ Jr, Gergen PJ, Vaughn B, Zeldin DC. Asthma cases attributable to atopy: results from the Third National Health and Nutrition Examination Survey. J Allergy Clin Immunol. 2007;120(5):1139\u201345.","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"2230_CR23","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1111\/cea.12963","volume":"47","author":"H Backman","year":"2017","unstructured":"Backman H, Raisanen P, Hedman L, Stridsman C, Andersson M, Lindberg A, Lundback B, Ronmark E. Increased prevalence of allergic asthma from 1996 to 2006 and further to 2016\u2014results from three population surveys. Clin Exp Allergy. 2017;47(11):1426\u201335.","journal-title":"Clin Exp Allergy"},{"issue":"4","key":"2230_CR24","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/cea.13790","volume":"51","author":"M Chen","year":"2021","unstructured":"Chen M, Shepard K 2nd, Yang M, Raut P, Pazwash H, Holweg CTJ, Choo E. Overlap of allergic, eosinophilic and type 2 inflammatory subtypes in moderate-to-severe asthma. Clin Exp Allergy. 2021;51(4):546\u201355.","journal-title":"Clin Exp Allergy"},{"key":"2230_CR25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12890-019-1040-2","volume":"20","author":"J Pakkasela","year":"2020","unstructured":"Pakkasela J, Ilmarinen P, Honkamaki J, Tuomisto LE, Anders\u00e9n H, Piiril\u00e4 P, Hisinger-Molkanen H, Sovijarvi A, Backman H, Lundback B, et al. Age-specific incidence of allergic and non-allergic asthma. BMC Pulm Med. 2020;20:9.","journal-title":"BMC Pulm Med"},{"key":"2230_CR26","doi-asserted-by":"crossref","unstructured":"Chhiba KD, Patel GB, Vu THT, Chen MM, Guo A, Kudlaty E, et al. Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19. J Allergy Clin Immunol. 2020;146(2):307\u201314.e4.","DOI":"10.1016\/j.jaci.2020.06.010"},{"issue":"1","key":"2230_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14581","volume":"34","author":"T Naziroglu","year":"2021","unstructured":"Naziroglu T, Aksu K. Rare atopy in COVID-19 patients or COVID-19 famine in atopic patients? Dermatol Ther. 2021;34(1): e14581.","journal-title":"Dermatol Ther"},{"issue":"4","key":"2230_CR28","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.anai.2020.07.012","volume":"125","author":"A Keswani","year":"2020","unstructured":"Keswani A, Dhana K, Rosenthal JA, Moore D, Mahdavinia M. Atopy is predictive of a decreased need for hospitalization for coronavirus disease 2019. Ann Allergy Asthma Immunol. 2020;125(4):479\u201381.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2230_CR29","doi-asserted-by":"crossref","unstructured":"Jackson DJ, Busse WW, Bacharier LB, Kattan M, O\u2019Connor GT, Wood RA, et al. Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2. J Allergy Clin Immunol.\u00a02020;146(1):203\u20136.e3.","DOI":"10.1016\/j.jaci.2020.04.009"},{"issue":"3","key":"2230_CR30","doi-asserted-by":"publisher","first-page":"841","DOI":"10.3390\/jcm9030841","volume":"9","author":"SJ Brake","year":"2020","unstructured":"Brake SJ, Barnsley K, Lu W, McAlinden KD, Eapen MS, Sohal SS. Smoking upregulates angiotensin-converting enzyme-2 receptor: a potential adhesion site for novel coronavirus SARS-CoV-2 (Covid-19). J Clin Med. 2020;9(3):841.","journal-title":"J Clin Med"},{"key":"2230_CR31","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12933-021-01275-w","volume":"20","author":"M Herman-Edelstein","year":"2021","unstructured":"Herman-Edelstein M, Guetta T, Barnea A, Waldman M, Ben-Dor N, Barak Y, Kornowski R, Arad M, Hochhauser E, Aravot D. Expression of the SARS-CoV-2 receptorACE2 in human heart is associated with uncontrolled diabetes, obesity, and activation of the renin angiotensin system. Cardiovasc Diabetol. 2021;20:90.","journal-title":"Cardiovasc Diabetol"},{"key":"2230_CR32","doi-asserted-by":"crossref","unstructured":"Branco ACCC, Sato MN, Alberca RW. The possible dual role of the ACE2 receptor in asthma and coronavirus (SARS-CoV2) infection. Front Cell Infect Microbiol. 2020;10:550571.","DOI":"10.3389\/fcimb.2020.550571"},{"key":"2230_CR33","doi-asserted-by":"crossref","unstructured":"Kimura H, Francisco D, Conway M, Martinez FD, Vercelli D, Polverino F, et al. Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells. J Allergy Clin Immunol. 2020;146(1):80\u20138.e8.","DOI":"10.1016\/j.jaci.2020.05.004"},{"issue":"1","key":"2230_CR34","doi-asserted-by":"publisher","first-page":"5139","DOI":"10.1038\/s41467-020-18781-2","volume":"11","author":"SP Sajuthi","year":"2020","unstructured":"Sajuthi SP, DeFord P, Li Y, Jackson ND, Montgomery MT, Everman JL, Rios CL, Pruesse E, Nolin JD, Plender EG, et al. Type 2 and interferon inflammation regulate SARS-CoV-2 entry factor expression in the airway epithelium. Nat Commun. 2020;11(1):5139.","journal-title":"Nat Commun"},{"issue":"1","key":"2230_CR35","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s12016-020-08797-3","volume":"59","author":"S Liu","year":"2020","unstructured":"Liu S, Zhi Y, Ying S. COVID-19 and asthma: reflection during the pandemic. Clin Rev Allergy Immunol. 2020;59(1):78\u201388.","journal-title":"Clin Rev Allergy Immunol"},{"key":"2230_CR36","doi-asserted-by":"crossref","unstructured":"Camiolo M, Gauthier M, Kaminski N, Ray A, Wenzel SE. Expression of SARS-CoV-2 receptor ACE2 and coincident host response signature varies by asthma inflammatory phenotype. J Allergy Clin Immunol. 2020;146(2):315\u201324.e7.","DOI":"10.1016\/j.jaci.2020.05.051"},{"issue":"4","key":"2230_CR37","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1165\/rcmb.2021-0364OC","volume":"66","author":"LR Bonser","year":"2022","unstructured":"Bonser LR, Eckalbar WL, Rodriguez L, Shen J, Koh KD, Ghias K, Zlock LT, Christenson S, Woodruff PG, Finkbeiner WE, et al. The type 2 asthma mediator IL-13 inhibits SARS-CoV-2 infection of bronchial epithelium. Am J Respir Cell Mol Biol. 2022;66(4):391\u2013401.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2230_CR38","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13223-020-00461-x","volume":"16","author":"MM Wong","year":"2020","unstructured":"Wong MM, Keith PK. Presence of positive skin prick tests to inhalant allergens and markers of T2 inflammation in subjects with chronic spontaneous urticaria (CSU): a systematic literature review. Allergy Asthma Clin Immunol. 2020;16:72.","journal-title":"Allergy Asthma Clin Immunol"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-022-02230-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-022-02230-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-022-02230-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T08:09:04Z","timestamp":1668413344000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-022-02230-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,14]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2230"],"URL":"https:\/\/doi.org\/10.1186\/s12890-022-02230-5","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,14]]},"assertion":[{"value":"5 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"To protect patient anonymity and confidentiality in compliance with the Health Insurance Portability and Accountability Act of 1996, all data used in this analysis were deidentified. The study was conducted according to the International Conference on Harmonisation E6 Guidelines for Good Clinical Practice and the principles of the Declaration of Helsinki 2013. Administrative permissions were not required to access the data. The study did not require institutional review board approval as this research falls under the HIPPA Privacy Rule for Research, Limited Data Sets with a Data Use Agreement. A data use agreement was entered into by both the covered entity (Optum Inc COVID-19 database) and the researcher (Genentech Inc), pursuant to which the covered entity may disclose a limited data set to the researcher for research, public health, or health care operations. See 45 CFR 164.514(e).Information on Optum.\u00ae de-identified COVID-19 Electronic Health Record dataset (2007\u20132021), August 2021Given the urgent need to clinically understand the novel virus of COVID 19, Optum developed a low latency data pipeline that enables minimal data lag, while preserving as much clinical data as possible. The data is sourced from Optum\u2019s longitudinal EHR repository, which is derived from dozens of healthcare provider organizations in the United States, including more than 700 Hospitals and 7000 Clinics. The data is certified as de-identified by an independent statistical expert following HIPAA statistical de-identification rules (Guidance Regarding Methods for De\u2010identification of Protected Health Information in Accordance with the Health Information Insurance Portability and Accountability Act (HIPAA) Privacy Rule (Dated as September 4, 2012, as first released on November 26, 2012) and managed according to Optum\u00ae customer data use agreements.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The study did not require consent for publication approval because only deidentified data were included. See information on the Optum Inc. database above.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TRM has been part of speaker bureaus for ALK, AstraZeneca, Boehringer Ingelheim, Genentech, Inc., and Optinose, and an advisory board member for Stallergenes Greer. WB has received grant support from the National Institutes of Health (NIH)-National Institute of Allergy and Infectious Diseases, and consultant fees from AstraZeneca, Genentech, Inc., GlaxoSmithKline, Novartis, and Sanofi\/Regeneron. CTJH, YR, and CSM\u00a0are former employees of Genentech, Inc. AS holds stock in F. Hoffmann-La Roche Ltd. KR, AS, SG, and AI are employees of Genentech, Inc. RJK has consulted for Boehringer Ingelheim, Genentech, Inc., and United Therapeutics; has received research support from Boehringer Ingelheim and the NIH; was a clinical investigator for Bellerophon, the NIH, Respivant, and Toray; and was on the data and safety monitoring board for Pliant and PureTech.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"418"}}